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ABSTRACT 
Background & objectives: 
Since antidepressants are prescribed for multiple indications, the use of an antidepressant cannot be 
equated with a diagnosis of depression.  
The objective of this study was to examine the quality of antidepressant prescribing in Belgian nursing 
homes with a critical evaluation of indications and dosages: to see whether depression was appropriately 
treated in terms of drug choice, indications and/or under-dosing. 
Methods: 
Clinical and medication data was obtained from a cross-sectional study of a representative stratified 
random sample of 1730 residents from 76 Belgian nursing homes (PHEBE study 2006). A 28-item 
checklist of clinical conditions was ad hoc designed for the PHEBE study and sent to the general 
practitioner (GP) to collect clinical information. We copied the medication chart, classified the drugs into 
codes with the Anatomical Therapeutic and Chemical classification system, and transferred the drug 
names and dosages into a database. Information on indications was retrospectively obtained from the 
GP, so that we could link the indication to each medication. Minimal effective doses (MED) of 
antidepressants to treat major depression were obtained from literature to assess under-dosing.  
Results: 
The overall use of antidepressants in nursing homes was 39.5% [95%CI, 37.2-41.8]. The physicians 
labelled 34.2% [95% CI 32.0-36.4] of the residents as having a depression and 80.9% of them were 
treated with an antidepressant. 
Indications among the single antidepressant users (n= 551) were ‘depression’ (66.2%), ‘insomnia’ 
(13.4%), ‘anxiety’ (6.2%) and ‘neuropathic pain’ (1.6%). 
In the indication of ‘depression’, 74.8% used a Selective Serotonine Reuptake Inhibitor (SSRI), 
predominantly citalopram, sertraline and escitalopram. Venlafaxine was used by 10.7% of the residents. 
Dosages for these antidepressants were equal to or higher than the MED. But when trazodone, 
amitriptyline or mirtazapine was used to treat depression, respectively 92.3%, 55.5% and 44.5% was 
dosed under the MED.  
In the indication of ‘insomnia’ most of the time trazodone (90.5%) or mirtazapine (5.4%) was used and in 
lower dosages than required for depression treatment (<MED). Tricyclic antidepressants were 
predominantly used for the treatment of neuropathic pain and also at lower dosages. Of all the residents 
receiving a medication for ‘anxiety’, only 13.9% received an antidepressant (mostly a SSRI), and the 
remaining received a benzodiazepine.  
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Conclusion: 
The number one indication for the use of an antidepressant was depression. Within this indication, 
mostly the recommended SSRIs were used in dosages equal to or higher than the MED. Furthermore, we 
noticed that there was a substantial use of sedative antidepressants for insomnia and that the physicians 
preferred the use of benzodiazepines over the recommended SSRIs to treat anxiety chronically. 
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ORIGINAL RESEARCH ARTICLE 
INTRODUCTION 
The prevalence of late-life depression in nursing homes varies from 11% to 50% [1-5] and is generally 
higher than in community dwelling older adults [6]. Depression is often reported to be under-recognised 
and undertreated in older adults [3, 7]. However, the use of antidepressants (ADs) increased over the last 
decade [8] and this trend was also visible in the nursing home population [9, 10].  
Depression often has an atypical presentation in older adults [11]. The poor recognition of clinical features 
of depression in old age and the overlap with symptoms of dementia or other co-morbidities makes a 
correct diagnosis difficult.  
Depression negatively affects daily activities [12], the quality of life [13], causes high treatment and societal 
costs[14, 15] and increases mortality [16]. Chronic diseases, pain and social deprivation are known risk 
factors for developing a depression [17]. These elements are common in long-term care facilities. 
Moreover, transition from the community to a nursing home can trigger depression, which results in the 
high number of newly admitted residents developing a depression [2, 18].  
Depression is a treatable illness [19]; approximately 50-60% patients with major depressive disorder are 
thought to improve clinically as a consequence of antidepressant treatment[20, 21]. In addition, there are 
other indications to prescribe an antidepressant. Anxiety, panic disorders, behavioural and psychological 
symptoms of dementia and neuropathic pain [22] are the potential indications of antidepressant 
prescribing in the older population. In daily practice, antidepressants are also prescribed for insomnia 
without concomitant depressive symptoms, although this indication is not mentioned in the official 
labelling [23]. 
In order to make a profound evaluation of the antidepressant prescribing attitude and to evaluate the 
pharmacotherapy of depression, both indication and dosage information are necessary. Drug utilisation 
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studies that evaluate the indication and dosages of these medications are scarce [24-26]. In these studies, 
indication analysis is mostly done by linking clinical diagnoses (ICD-9 or DSM IV) and medication 
databases. This does not automatically provide information for which reason/indication each 
antidepressant is prescribed. Similar to the BEACH project in Australia [27], the PHEBE study (Prescribing 
in Homes for the Elderly in Belgium) was designed to include the indication per medication as indicated 
by the prescribing general practitioner (GP). The PHEBE study was a cross-sectional, descriptive study of 
a representative stratified random sample of 76 Belgian nursing homes, investigating the overall drug 
utilisation in Belgian nursing homes in 2006. A detailed description of the methods and findings of this 
study was published elsewhere[28-30]. 
The objective of this subanalysis of the data obtained in the PHEBE study was to examine the quality of 
antidepressant prescribing in Belgian nursing homes with a critical evaluation of indications and dosages: 
to see whether depression was appropriately treated in terms of drug choice, indications and/or under-
dosing. An additional objective was to investigate the resident characteristics associated with 
antidepressant use. 
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METHODS 
Setting 
Belgium has a mixed, public/private health care system. The system works on a fee for service base. The 
Belgian long-term residential care structure consists of residential and/or nursing homes for older 
people, which offer a home replacement with or without nursing care. Governance of nursing homes for 
older people is either public (community health services) or private (predominantly non-profit) with little 
difference in quality. In Belgian nursing homes, residents are still supervised by their own GP, and this 
leads to an average of 32 GPs per nursing home. 
Data collection 
In the PHEBE study, data collection at resident level included administrative, clinical and medication 
data. We obtained the medication data by copying the medication chart, transferring and coding it to a 
database. For collecting clinical data, we sent the GP a checklist with 28 items, focusing on clinical 
problems (i.e. cardiovascular disease, COPD, peptic ulcer) as well as focusing on care problems (i.e. 
problems with a predominant nursing care burden, such as dementia, insomnia, depression,…). The 28-
item checklist of clinical conditions was ad hoc designed for this study, with the items selected based on 
existing prescribing quality indicators (BEERS[31], ACOVE[32], BEDNURS[33]) for older adults. The diagnosis 
of depression is in this study based on the clinical evaluation by the GP. In Belgium, the KATZ scale is a 
mandatory instrument in the nursing homes and it consist of two parts. The first part scores activities of 
daily living (ADL) and the second part scores disorientation in time and place. This second part is scored 
from 1 (no disorientation) to 5 (severe) and used as a proxy to estimate the severity of dementia in this 
study.  Residents receiving palliative care were excluded from analysis.  
Classification of Antidepressants 
Antidepressants were classified according to the Anatomical Therapeutic Classification system (ATC) [34]. 
According to the availability on the Belgian pharmaceutical market, we investigated the classes N06AA 
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Tricyclic Antidepressants (TCA), N06AB Selective Serotonin Reuptake Inhibitors (SSRI), N06AG Mono 
Amino Oxidase Inhibitors (MAO-I) and the class N06AX which includes serotonin-norepinephrine 
reuptake inhibitors and other antidepressants. 
The SNRI, duloxetine, and bupropion are not included in the analysis because they were not yet 
commercialised in Belgium in 2006. Lithium, in ATC considered as an antipsychotic and mostly used to 
treat bipolar disorders, was excluded from analysis. Combination drugs of an antidepressant and an 
antipsychotic were also excluded. Duplicate use therapy was defined as the concomitant use of 2 or 
more ADs. Medication prescribed in short term and as-needed medications were excluded from analysis. 
We focused on chronic use (defined as daily use for at least 3 months). 
We analysed 2 levels of describing AD use: the prescription (medication) and the resident level. 
Indications were analysed at prescription and resident level and dosages at prescription level only. 
Indication and dosages 
Data on indications were collected retrospectively: the GP received a printout of the resident’s 
medication chart for verification of the medication use, and he/she was asked to tick relevant indications 
from a predefined list for ADs: depression, posttraumatic stress, anxiety, insomnia, neuropathic pain or 
other. 
The prescribed daily dose (PDD) of each AD was recorded by summing the doses taken at the different 
moments of intake during one day. To interpret these doses, we chose the universal Defined Daily Dose 
(DDD), which is the assumed average maintenance dose per day for a drug used for its main indication in 
adults[34]. We described the distribution of the PDD using its median and range. To examine possible 
under-dosing in the treatment of depression, we used the Minimal Effective Dose (MED). The MED of an 
antidepressant serves as a threshold, below which all doses are not effective in treating major depressive 
episode [35]. The MED of the most common antidepressants were determined using the Prescribing 
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guidelines [36] and Pharmacotherapy: A pathophysiologic Approach [37]. We considered under-dosing 
when the PDD of the antidepressant was under the MED. 
Statistical analysis. 
The data was analysed using the statistical package SPSS version 18. The alpha level of significance was 
set at p< 0.05. We used descriptive statistics to explore indications and dosages.  
We examined the characteristics (demographical, clinical, medication and institutional information) of 
the AD users and the nonusers, and also compared characteristics of the AD users for the different 
indications (respectively for depression and all other indications). To investigate differences, we used χ² 
for discontinue variables, t-tests for continuous variables or non-parametric statistics (Mann-Whitney U 
test) for skewed distributions. 
In a second analysis, we explored a risk profile for AD use. We calculated the Odds ratios and the 95% 
confidence intervals in univariate and multivariate analysis. For multivariate analysis, we used a stepwise 
regression model including the statistical significant variables from the univariate analysis.  
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RESULTS 
Study population characteristics. 
Medication data and clinical information of 1730 nursing home residents was included in the analysis. 
The mean age was 85 (range 60-104) and 78.1% was female. The prevalence of depression was 
34.2%[95% CI 32.0-36.4]. In 14.9% of the residents a combination of depression and dementia was 
noted.  
The mean number of chronic medication per resident was 7, ranging from no medication (in less than 1% 
of the residents) to 22. The most frequently used drugs among the residents were the central nervous 
system drugs, with benzodiazepine, antidepressant, antipsychotic and anti-dementia drug prevalence in 
respectively 53.1%, 39.5%, 32.9% and 8.3% of all residents. The demographical and clinical 
characteristics of the study population are shown in table I. 
Antidepressant use at Resident level: prevalence and indications. 
The prevalence of chronic AD utilisation among 1730 residents was 39.5%[95% CI 37.2-41.8]. The use of 
a single AD was seen in 32.6% , while the concomitant use of 2 to 4 ADs was found in 6.9%. Among the 
antidepressant users, using a single AD (n=551), the leading indication for this use was ‘depression’ 
(66.2%), followed by ‘insomnia’ (13.4%), ‘anxiety’ (6.2%) and ‘pain’ (1.6%). We found the use of a single 
AD for ‘multiple indications’ in 11.6%. It consisted largely of depression associated with another 
indication (Table II).  
The physicians labelled 34.2% [95% CI 32.0-36.4] of the residents as depressed and 80.9% of them were 
treated with an AD; more specific indication analysis showed that 73.1% of the residents with noted 
depression received an AD for that very indication (Table II).  
Table III shows which AD was most used for which indication. When the indication of the AD was 
‘depression’, 74.8% of the residents took a SSRI, 10.7% venlafaxine and 8.2% mirtazapine. For the single 
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indication ‘insomnia’ and for the combination of ‘insomnia and depression’, in respectively 90.5% and 
53.3% trazodone was used. When the indication of the AD was ‘anxiety’, different AD classes were used, 
but mostly SSRIs (64.7%), trazodone (14.7%) and venlafaxine (8.8%). Of all residents receiving a 
medication for anxiety only 13.9% received an AD (mostly an SSRI) and the remaining received a 
benzodiazepine. The indication of ‘neuropathic pain’ was mostly treated with TCA (66.7%) (Table III).  
Antidepressant use at Prescription level: prevalence and dose analysis. 
The most frequently prescribed class of all 814 AD prescriptions was SSRI (52.8%) with citalopram, 
sertraline and escitalopram accounting for respectively 17.1%, 14.5% and 10.2%. Trazodone, which is a 
serotonin modulator, was the most prescribed molecule (22.9%). Venlafaxine was found in 8.2% and 
mirtazapine was found in 7.7% of all AD prescriptions. The TCA group accounted for 5.8% with 
amitriptyline (3.6%) as the most representative TCA drug. MAO-I prescriptions were negligible (0.1%) 
(Table IV).  
Of the 814 prescriptions, 72.5% was indicated for depression. Table IV shows the frequency of use of all 
ADs and dosing information of the most common ADs for this indication. The amount of prescriptions 
with PDD below the MED for the treatment of depression was high for trazodone (92.3%), amitriptyline 
(55.5%), and mirtazapine (44.5%). We did not observe this under-dosing when an SSRI or venlafaxine was 
prescribed. 
When we used the DDD as a reference, we saw that for the indication of insomnia, the physicians 
prescribed daily dosages below the DDD (98.2%); this was also the case for the treatment of 
(neuropathic) pain (87.5%). For anxiety, mostly 1 DDD (53.8%) or less than 1 DDD was prescribed 
(46.2%). 
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Characteristics associated with AD use. 
Univariate analysis showed that AD use was significantly associated with polypharmacy, peptic ulcer and 
some care problems such as depression, insomnia, pain and constipation. We registered a gradual 
decrease in AD use from the age of 80. In a public nursing home and where the medication was 
dispensed through a hospital pharmacy, there was less AD use (Table V). 
In multivariate analysis, AD use was more frequent in younger residents (OR 0.97, 95% CI 0.96-0.99), in 
residents with insomnia (OR 1.59, 95%CI 1.26-2.01) and in private nursing homes (OR 1.54, 95%CI 1.25-
1.90). AD use was also more likely in residents with more chronic use of medications (OR 1.15 95%CI 
1.11-1.19), concomitant use of benzodiazepines (OR 1.28, 95%CI 1.00-1.62), antipsychotics (OR 1.26, 
95%CI 1.01-1.57), anti-dementia medication (OR 1.54, 95%CI 1.07-2.23) and antiparkinson medication 
(OR 1.58, 95%CI 1.14-2.18) (Table V). 
Characteristics associated with Antidepressant use for the indication ‘depression’ and 
‘other’ indications. 
Residents who received an AD for the indication of depression had more chronic obstructive pulmonary 
disease and had a significant larger usage of (chronic) medication in comparison to the residents that 
received an AD for other indications. The residents that received an AD for other indications were more 
likely to be labelled by their physician as insomniacs (Table V). 
Depression and dementia 
In more than one third (34.4%) of the nursing home residents with some form of dementia, the GP 
recorded depression. The prevalence of noted depression as well as the use of an AD for the indication 
depression decreased as dementia progressed. On the other hand, the proportion of AD use for other 
indications slightly increased in patients with more advanced dementia (Figure 1).  
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DISCUSSION 
 
To our knowledge, our study is the first European study to collect indication and dosage information of 
each antidepressant directly from the treating physician. Based on our results, we cannot state that 
depression is undertreated in the Belgian nursing homes. More than one third of Belgian nursing home 
residents were labelled with depression and 81% of them were treated with an AD. The prescribing 
physicians used suitable drug classes according to the guidelines for depression in older people [38]. 
Under-dosing was not seen in the treatment of depression with the most prevalent AD classes, but when 
ADs were used for other indications, we saw the use of lower doses. 
There was a substantial use of ADs (mainly trazodone) for insomnia. Furthermore, we noticed physicians 
were more likely to prescribe a benzodiazepine rather than the preferred SSRIs to treat (chronic) anxiety.  
STRENGHTS AND LIMITATIONS 
Our sample has proved to be representative both on institutional and on residential level[39]. Moreover, 
the large size of our sample makes it possible to extrapolate our findings to the entire Belgian nursing 
home setting.  Similar prevalence numbers of depression and AD use were found in European [1, 40] and 
American [9] studies, but for specific indication and dosage evaluation, no identical studies were 
available. The indications of AD prescribing were retrospectively collected by interviewing the GP. As the 
GP is the prescriber of the AD, this approach gives us a clearer view of the use of ADs rather than linking 
clinical diagnoses and medication databases. This strength can be a limitation as well due to the 
retrospective aspect. Our interpretation of under-dosing and the MED as a threshold was established by 
using a strict methodology (see methods).  
A limitation of our study is that we did not collect information about alternative treatment strategies for 
depression such as psychotherapy, so we focus our discussion on the residents receiving an AD. Another 
16 
 
limitation is that we did not use validated diagnostic criteria to evaluate (severity) of depression and 
dementia, but we relied on the a posteriori clinical judgement of the treating physician. The physicians 
should have been aware that depression is not equal to depressive mood, but we don’t know whether 
they had fully considered this. Moreover, we had no breakdown of various degrees of depression in our 
checklist of clinical diagnoses. The disorientation axes of the KATZ scale may not be an ideal dementia 
grading instrument as it can be influenced by other disorders (depression, delirium). However, we 
decided to use this tool for pragmatic reasons, because it is mandatory in the Belgian context, and thus 
the data are readily available. In addition, in this cross-sectional study, we were not able to investigate 
the distribution of the duration of AD use nor was it possible to investigate temporal changes and the 
relationship between process and outcome. Furthermore, we reduced the complexity of the analysis by 
narrowing our in depth analysis of indications to single AD users, and we disregarded residents on more 
than one AD (6.9% of all residents).  
DISCUSSION of the MAIN FINDINGS 
According to our study, in more than one third of the Belgian nursing home residents the treating 
physician noted depression. This percentage is situated in the middle segment of the prevalence range 
11%-50% reported in other studies in different western countries [1, 3-5]. Of all the residents labelled with 
depression, 81% was treated with an AD and 73% received an AD especially for the indication 
depression. Knowing that only major depressions should be treated pharmacologically, our results do 
not support the hypothesis of undertreatment in the group of residents with noted depression. Other 
recent articles also indicate an AD treatment percentage of more than 80% [9, 40] for depressed residents, 
but these percentages are irrespective of indication. In addition to reporting that there is no 
undertreatment, it could also be useful to examine the reason why about a third of all residents need a 
pharmacological treatment of their depression. 
17 
 
In our study, more than one quarter of the AD prescriptions (28%) was not to treat depression. Other 
approved indications such as anxiety and neuropathic pain accounted for 7.8% of all AD use. Insomnia 
without depressive symptoms accounted for 13.4%. 
Most of the ADs were prescribed at a dosage of 1 DDD or less and rarely exceeded 1 DDD. Possible 
depression under-dosing in the nursing home population was checked by analysing the prescribed daily 
dose in accordance to the MED. The SSRI group and venlafaxine were dosed above their MED. 
Trazodone, TCAs and mirtazapine were often dosed under their MED. It is important to keep in mind that 
when treating older adults, polypharmacy, polypathology, pharmacokinetic and –dynamic alterations can 
influence dosage response. The MED does not really consider these particular changes in determining 
the threshold. In literature, there is not much guidance on dosing of antidepressants in frail older adults; 
slow upwards titration and close monitoring of side-effects is recommended [41]. 
Antidepressants for the indication ‘depression’ 
For the indication of depression in old age, SSRIs deserve a preference within the pharmacological 
approach [38, 42] and as found in our study, were the most commonly prescribed ADs in Belgian nursing 
homes (citalopram, sertraline, escitalopram). Although SSRIs have a more appropriate side-effect profile 
and are safer in over-dose for older adults than other antidepressants, still, physicians should prescribe 
these drugs with caution, because of the risk of drug-drug interactions and adverse effects such as 
hyponatraemia[43], upper gastrointestinal bleeding[44], insomnia, restless leg syndrome, agitation and the 
potential risk of serotonin syndrome[45, 46]. The BEERS list [31] discourages the use of fluoxetine in older 
adults, due to its long half-life and inhibition of cytochrome P 450 enzymes (mainly CYP2D6). In our study 
this SSRI was prescribed only in 2% of the cases.  
In our study, venlafaxine was also frequently prescribed for depression. Together with the SSRIs, it is 
known for its stimulating properties that can cause sleeplessness [47]. Venlafaxine should be reserved as a 
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second-line treatment for depression and is not indicated in patients with heart failure, coronary disease 
and uncontrolled hypertension [38].  
Mirtazapine is also a relatively often prescribed AD for older adults because it has less anti-cholinergic 
side effects (i.e. dry mouth, urinary retention, constipation) than TCAs [48].  
TCAs, equally effective as SSRIs [49], are known for their toxicity in overdose [50] and their anti-cholinergic 
side-effect profile. Therefore, they are not recommended as a first choice to treat depression in older 
adults. However, a recent cohort study concluded that SSRIs and the newer ADs were associated with a 
higher risk of adverse events, such as stroke, fracture and all-cause mortality, compared with TCAs  [40].  
In our study, SSRIs and venlafaxine are prescribed above the MED. However, 45% of the mirtazapine, 
96% of the trazodone and 56% of the TCA prescriptions are dosed under their MED, a possible 
precaution of prescribers aware of the sedative and/or anti-cholinergic properties of these drugs. 
Antidepressants for ‘other’ indications 
The most frequently prescribed AD in this setting was trazodone. It was predominately prescribed at 
lower dosages for primary insomnia. The use of trazodone for sleep disturbance in adult and older 
patients is extensive in clinical practice [51].  In depressed adult patients, there is evidence for the efficacy 
of trazodone for sleep disturbance [52]. In non-depressed adult patients, trazodone might be effective in 
primary insomnia[53]. However, the evidence for its use for primary insomnia in older people is rather 
scarce [23] and controversial [54]. Trazodone has so far not received an indication as sleep-promoting agent 
in the official labelling. The side effects of trazodone are not very different from other 
(non)benzodiazepine hypnotics in terms of residual daytime impairments, but priapism and orthostatic 
hypotension are important side effects of trazodone [55]. 
The amount of trazodone prescriptions intended for insomnia and not to treat depression is increasing 
[51, 56]. The (inter)national warnings and campaigns against the chronic use of benzodiazepines (OBRA 
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’87)[57] [15] are a possible reason for the preferential prescribing of trazodone. Another consideration can 
be the relatively lower cost of trazodone in Belgium in comparison to (non)benzodiazepine hypnotics. 
Moreover, trazodone, unlike (non)benzodiazepines hypnotics, is reimbursed (for 75%) by the Belgium 
Health Care system. In order to maintain a healthy economic situation, it is important to ensure that no 
shift towards reimbursed sedative ADs takes place, particularly in the absence of convincing evidence.  
Another indication for which an AD can be prescribed is neuropathic pain. Our study confirmed the 
assumption that TCAs are mostly prescribed for the treatment of pain [22], and at doses lower than the 
DDD [24]. Although not licensed for this indication, amitriptyline, which was in our study the most 
prevalent agent, is considered first-line treatment for neuropathic pain in guidelines[58]. Duloxetine is 
also indicated for neuropathic pain and is registered for this indication [58].  
Although the first pharmacological choice to treat anxiety disorders chronically is a SSRI [59, 60], in our 
study physicians were more likely to prescribe a benzodiazepine on a chronic base rather than an AD. 
Benzodiazepines can be used for acute anxiety or can be co-administered for a short period of time (max 
4 weeks) to overcome the delayed pharmacological effect of the AD  [59, 61, 62].  However, to avoid 
tolerance and dependence, this dual therapy should be tapered in time.  
Characteristics associated with antidepressant use. 
We found that older residents had a lower AD use. This is also mentioned in other AD studies [9, 17] and 
with other medication groups. This can be partly explained by the increasing incidence of dementia in 
older residents and the growing inability of residents to utter specific complaints (feeling depressed) 
with deepening dementia. We also found that psychotropic use and polypharmacy are inextricably 
linked, indicating the need for clinical practice guidelines and education focusing on initiation and 
reassessment of ADs and psychotropic use in general. Antiparkinson drugs were significantly associated 
with AD use which can be explained by the symptoms of Parkinsonism: depression is a common 
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neuropsychiatric manifestation in Parkinson's disease. As ADs may have sedative properties and are 
often used for the treatment of insomnia, it was no surprise that insomnia was correlated with AD use, 
and more specifically with AD use for other indications than depression. Because in Belgium the 
differences in institutional characteristics between a private and public nursing home are little, we 
cannot explain the association between the private nursing homes and the elevated likelihood of 
receiving an antidepressant. 
Depression and dementia 
In our study, in one third of the residents with noted dementia, also a depression was reported. This is 
higher than the prevalence rate in other European countries [5, 63] and the United States [64]. When 
analyzing the different stages of disorientation (expression of dementia), we found that both the 
prevalence of depression and the antidepressant use decreased with worsening disorientation. This 
could indicate the difficulty to diagnose depression in cognitive impaired residents and a possible under-
treatment in this specific patient group. However, a recent publication in the Lancet [65] suggested the 
absence of benefit of antidepressants in dementia compared to placebo and the increased risk of 
adverse events. The trial does not advocate the abandonment of antidepressants but underscores the 
need to think about creative, but evidence-based alternatives (such as psychosocial interventions) for 
the management of depression in people with dementia. But due to organizational- and staffing 
problems psychotherapy is not routinely available in Belgian nursing homes. 
CONCLUSION 
ADs were used by 39.5% of the residents. Overall, the quality of AD prescribing in the Belgian nursing 
homes is relatively satisfactory. Most of the residents with reported depression were treated according 
to evidence-based recommendations with SSRIs (mainly citalopram, sertraline and escitalopram) in 
dosages equal to or higher than the MED. Venlafaxine, not the first-choice drug in the older population, 
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was used in 1/10 and in dosages equal to or higher than the MED. All other antidepressants (TCAs, 
mirtazapine, trazodone) used for depression were dosed under the MED.  
In the indication of anxiety, most of the time, the physicians did not prescribe the recommended SSRIs, 
but they preferred the chronic use of benzodiazepines.  
A controversial issue is the prescribing of sedative ADs (mostly trazodone) for insomnia (13.4%). A 
plausible explanation for this prescribing without clear evidence of efficacy and safety in frail older adults 
can be found in the reimbursed status of ADs and the relatively lower cost of trazodone in comparison to 
other sleeping pills.   
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TABLES & FIGURES 
 
TABLE I   
Characteristics of the study population 
RESIDENT CHARACTERISTICS total population 
  n= 1730 
Demographical characteristics  
Age (mean + range) 84.8 [60-104] 
Gender (% female) 78.1 
Main Clinical problems(%)  
Cardiovascular 75.7 
Peptic ulcer 24.6 
COPD 17.2 
Diabetes 16.8 
Renal failure 12.6 
Hepatic problems 1.4 
Parkinson 8.3 
Main Care problems(%)  
Dementia 47.7 
Depression 34.2 
Insomnia 44.0 
Risk of falling 45.5 
Constipation 41.9 
Chronic pain 35.1 
Incontinence 35.9 
Medication Information  
Number of (mean + range)  
Medications 8.0 [0-22] 
Chronic Medications 7.1 [0-22] 
Use of Psychotropics (%) 77.7 
Benzodiazepines/z-drugs 53.1 
Antidepressants 39.5 
Antipsychotics 32.9 
Use of Antidementia drugs(%) 8.3 
Use of Antiparkinson drugs(%) 10.9 
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TABLE II   
Prevalence of Antidepressant (AD) use and Depression and the distribution of users per indication. 
 
Prevalence  n %  
total AD use (N=1730) 684 39.5  
single  AD use 565 32.6 
multiple AD use 119 6.9 
total prevalence of depression (N=1730) 591 34.2  
   
AD use among residents with depression (N=591) 478 80.9 
AD use specific for the indication depression among residents 
with depression (N=591) 
432 73.1 
   
Indications among single AD users (N=551*) n % 
Depression 365 66.2 
Insomnia 74 13.4 
Anxiety 34 6.2 
Pain 9 1.6 
Multiple indications 64 11.6 
 depression+ insomnia 22 4.0 
 depression+ anxiety 23 4.2 
 depression + pain 8 1.5 
Other indications 5 0.9 
*total residents receiving a single AD(n=565) corrected for 14 missing indications   
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TABLE III  
Distribution of Indications of (single) antidepressant (AD) use in Belgian nursing home residents (at 
resident level).  
ANTIDEPRESSANT INDICATIONS for Antidepressant use among nursing home residents* 
    Depression Insomnia Anxiety Pain Multiple  
           n= 365      n= 74    n= 34    n=9      n=64 
TCA (=N06AA) 8 (2.2%) 1 (1.4%) 2 (5.9%) 6 (66.7%) 4 (6.2%) 
Amitriptyline 3 (0.8%)  2 (5.9%) 5 (55.6%)  
       
SSRI (=N06AB) 273 (74.8%) 1 (1.4%) 22 (64.7%) 1 (11.1%) 30 (46.9%) 
Citalopram 91 (24.9%) 1 (1.4%) 5 (14.7%) 1 (11.1%) 7 (10.9%) 
Sertraline 67 (18.4%)  7 (20.6%)  9 (14.1%) 
Escitalopram 60 (16.4%)  3 (8.8%)  3 (4.7%) 
Paroxetine 39 (10.7%)  7 (20.6%)  10 (15.6%) 
Fluoxetine 16 (4.4%)    1 (1.6%) 
       
MAO-I (=N06AG) 1 (0.3%)     
       
OTHERS (=N06AX) 83 (22.7%) 72 (97.3%) 10 (29.4%) 2 (22.2%) 30 (46.9%) 
Trazodone  10 (2.7%) 67 (90.5%) 5 (14.7%) 1 (11.1%) 18 (28.1%) 
Venlafaxine (=SNRI) 39 (10.7%)  3 (8.8%)  6 (9.4%) 
Mirtazapine 30 (8.2%) 4 (5.4%) 1 (2.9%) 1 (11.1%) 4 (6.3%) 
*n=551 (single AD users corrected for 14 missing indications); The indication 'others' is not shown (n=5) 
AD used by less than 10 residents are not shown:     
 TCA: dosulepine, imipramine,clomipramine,doxepine, nortriptyline, maprotiline  
OTHERS: mianserine, reboxetine, hypericum perforatum and moclobemide (MAO-I)  
       
TCA= Tricyclic Antidepressant; SSRI= selective serotonin reuptake inhibitor; MAO-I=monoamino oxidase inhibitor 
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TABLE IV 
Distribution of Antidepressants (AD) prescribed in Belgian nursing homes and dose information for the 
indication ‘depression’ (at prescription level) 
ANTIDEPRESSANTS 
TOTAL number of 
Prescriptions 
(n=814) 
  Prescriptions for  
depression  
(n= 590) 
PDD  MED 
number of 
prescriptions 
indicated for 
depression below 
MED 
median (range)   
TCA (=N06AA) 47 (5.8%) 22 (3.7%)    
Amitriptyline 29 (3.6%) 9 (1.5%) 25mg (10-50) 50mg 5 (55.5%) 
      
SSRI (=N06AB) 430 (52.8%) 386 (65.4%)    
Citalopram 139 (17.1%) 128 (21.7%) 20mg (10-40) 20mg 16 (12.5%) 
Sertraline 118 (14.5%) 103 (17.5%) 50mg (10-100) 50mg 9 (8.9%) 
Escitalopram 83 (10.2%) 77 (13.1%) 10mg (5-20) 10mg 15 (19.5%) 
Paroxetine 69 (8.5%) 58 (9.8%) 20mg (10-40) 10mg 0 
Fluoxetine 22 (2.1%) 20 (3.4) 20mg (10-20) 10mg 0 
      
OTHERS (=N06AX) 336 (41.3%) 181 (30.7%)    
Trazodone  186 (22.9%) 52 (8.8%) 100mg (50-150) 150mg 48 (92.3%) 
Venlafaxine  67 (8.2%) 61 (10.3%) 75mg (37.5-300) 75mg 3 (4.9%) 
Mirtazapine 63 (7.7%) 54(9.2%) 30mg (7.5-30) 30mg 24 (44.5%) 
ADs with less than 10 prescriptions are not shown:  
MAO-I: Moclobemide  n=1     
TCAs:  Dosulepine n=8, Imipramine n=4, Clomipramine n=2, Doxepine n=2, Nortriptyline n=1, Maprotiline n=1 
OTHERS: Mianserine n=10 ; Reboxetine n=5; Hypericum=5;     
      
PDD= prescribed daily dose (for depression); MED= Minimum Effective Dose (for 
depression)   
TCA= Tricyclic Antidepressant; SSRI= selective serotonin reuptake inhibitor; MAO-I=monoamino oxidase inhibitor 
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TABLE V 
Factors associated with Antidepressant use (AD). 
CHARACTERISTICS NON user RISK CALCULATION**
Total for depression for other indications UNIVARIATE MULTIVARIATE
N=1046 N= 684 N= 522 N= 162 p * OR(95% CI) OR(95% CI)
Demographical characteristics
Age (mean + range) 85.7 [60-104] 83.5 [60-102] 83.5 [60-102] 83.6 [60-102] 0.897 0.97(0.96-0.98) 0.97(0.96-0.99)
Gender (% female) 77.6 78.4 80.1 74.7 0.143 1.03(0.82-1.31)
Main Clinical problems(%)
Cardiovascular 75.0 75.8 77.4 74.7 0.477 1.09(0.81-1.26)
Peptic ulcer 22.1 27.8 29.6 24.7 0.230 1.33(1.07-1.67)
COPD 16.0 18.9 20.9 13.0 0.024 1.22(0.95-1.57)
Diabetes 16.3 17.4 18.7 14.8 0.264 1.06(0.82-1.37)
Renal failure 12.3 12.8 13.1 13.0 0.977 1.05(0.77-1.37)
Hepatic problems 1.2 1.6 1.5 1.9 0.780 1.25(0.56-2.80)
Parkinson 7.3 9.8 10.8 7.4 0.212 1.36(0.97-1.91)
Main Care problems(%)
Dementia 47.3 48.0 47.0 52.8 0.202 1.02(0.84-1.24)
Depression 11.5 70.3 84.2 29.2 p<0.001 18.07(13.99-23.34) ***
Insomnia 36.1 54.8 52.7 66.7 0.002 2.09(1.72-2.55) 1.59(1.26-2.01)
Risk of falling 43.9 47.8 48.6 45.6 0.516 1.17(0.97-1.42)
Constipation 39.1 45.3 45.1 49.7 0.306 1.27(1.04-1.54)
Chronic pain 32.6 38.3 40.8 32.7 0.066 1.27(1.04-1.55)
Incontinence 34.6 37.3 36.0 43.5 0.089 1.12(0.91-1.35)
Medication Information
Number of (mean + range)
Medications 7.1 [0-22] 9.2 [1-22] 9.5 [2-22] 8.9 [2-22] 0.012 1.15(1.12-1.18) ***
Chronic Medications 6.3 [0-22] 8.1 [0-22] 8.5 [2-21] 7.8 [2-19] 0.008 1.18(1.14-1.21) 1.15(1.11-1.19)
Use of Psychotropics (%)
Benzodiazepines/z-drugs 47.9 63.9 64.6 58.6 0.173 1.99(1.63-2.42) 1.28(1.00-1.62)
Antipsychotics 30.5 38.1 36.4 37.7 0.772 1.47(1.20-1.80) 1.26(1.01-1.57)
Use of Antidementia drugs 8.2 10.4 9.4 5.6 0.126 1.58(1.12-2.22) 1.54(1.07-2.23)
Use of AntiParkinson drugs 9.6 14.9 14.2 9.3 0.104 1.95(1.44-2.64) 1.58(1.14-2.18)
Institutional(%)
>90 beds 50.8 49.6 49.8 46.3 0.435 0.97(0.90-1.18)
ownership: private 51.1 60.6 62.1 56.2 0.180 1.47(1.21-1.78) 1.54(1.25-1.90)
linked with hospital pharmacy 17.7 13.0 11.9 16.0 0.166 0.70(0.53-0.92)
*p value of difference between users for 'depression' and users for 'other' indications , using χ², t-test and Mann Whitney U 
**RISK calculation: Risk of receiving an Antidepressant expressed as Odds  Ratio (OR)
*** not included in multivariate analysis due to interacting effects
ANTIDEPRESSANT user
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FIGURE 1  
Antidepressant use in relation to increasing dementia (scored by the severity of disorientation axes in 
the KATZ scale) 
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